TScan Therapeutics, Inc. financial data

Symbol
TCRX on Nasdaq
Location
Waltham, MA
Fiscal year end
31 December
Latest financial report
04 Mar 2026

Key Ratios

Label TTM Value / Value Unit Change %
Current Ratio 753% % -1.6%
Debt-to-equity 72% % 25%
Return On Equity -79% % -32%
Return On Assets -46% % -21%
Operating Margin -1315% % 73%

Shares

Label TTM Value / Value Unit Change %
Entity Public Float $56,871,577 USD
Weighted Average Number of Shares Outstanding, Basic 129,777,415 shares 16%
Weighted Average Number of Shares Outstanding, Diluted 129,777,415 shares 16%

Income Statement

Label TTM Value / Value Unit Change %
Revenue from Contract with Customer, Excluding Assessed Tax $10,325,000 USD 267%
Research and Development Expense $114,150,000 USD 6.3%
General and Administrative Expense $31,988,000 USD 5.6%
Operating Income (Loss) $135,813,000 USD -0.74%
Net Income (Loss) Attributable to Parent $129,766,000 USD -1.8%
Earnings Per Share, Basic -1 USD/shares 12%
Earnings Per Share, Diluted -1 USD/shares 12%

Balance Sheet

Label TTM Value / Value Unit Change %
Cash and Cash Equivalents, at Carrying Value $152,406,000 USD -15%
Marketable Securities, Current $14,947,000 USD -89%
Assets, Current $157,208,000 USD -46%
Property, Plant and Equipment, Net $8,706,000 USD 20%
Operating Lease, Right-of-Use Asset $57,743,000 USD -10%
Assets $228,789,000 USD -38%
Accounts Payable, Current $1,241,000 USD -71%
Employee-related Liabilities, Current $4,145,000 USD -39%
Liabilities, Current $18,695,000 USD -48%
Operating Lease, Liability, Noncurrent $54,437,000 USD -10%
Other Liabilities, Noncurrent $278,000 USD 90%
Liabilities $105,666,000 USD -19%
Accumulated Other Comprehensive Income (Loss), Net of Tax $2,000 USD
Retained Earnings (Accumulated Deficit) $504,862,000 USD -35%
Stockholders' Equity Attributable to Parent $123,123,000 USD -49%
Liabilities and Equity $228,789,000 USD -38%

Popular Metrics

Label TTM Value / Value Unit Change %
Net Cash Provided by (Used in) Operating Activities $37,586,000 USD -28%
Net Cash Provided by (Used in) Financing Activities $525,000 USD -303%
Net Cash Provided by (Used in) Investing Activities $13,530,000 USD -63%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect $24,581,000 USD -444%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents $157,437,000 USD -14%
Interest Paid, Excluding Capitalized Interest, Operating Activities $569,000 USD -25%
Deferred Tax Assets, Valuation Allowance $161,258,000 USD 33%
Operating Lease, Liability $61,604,000 USD -5.7%
Depreciation $678,000 USD -46%
Payments to Acquire Property, Plant, and Equipment $1,532,000 USD 117%
Comprehensive Income (Loss), Net of Tax, Attributable to Parent $129,817,000 USD -1.9%
Lessee, Operating Lease, Liability, to be Paid $83,993,000 USD -11%
Property, Plant and Equipment, Gross $30,276,000 USD 17%
Operating Lease, Liability, Current $7,167,000 USD 57%
Lessee, Operating Lease, Liability, to be Paid, Year Two $13,329,000 USD 2.9%
Lessee, Operating Lease, Liability, to be Paid, Year One $12,958,000 USD 28%
Lessee, Operating Lease, Liability, Undiscounted Excess Amount $22,389,000 USD -22%
Lessee, Operating Lease, Liability, to be Paid, Year Three $13,712,000 USD 2.9%
Deferred Tax Assets, Operating Loss Carryforwards $48,477,000 USD 55%
Preferred Stock, Shares Issued 0 shares
Preferred Stock, Shares Authorized 10,000,000 shares 0%
Unrecognized Tax Benefits $0 USD
Lessee, Operating Lease, Liability, to be Paid, Year Four $13,354,000 USD -2.6%
Preferred Stock, Shares Outstanding 0 shares
Deferred Tax Assets, Net of Valuation Allowance $177,033,000 USD 27%
Interest Expense $2,769,000 USD -24%
Preferred Stock, Par or Stated Value Per Share 0.0001 USD/shares 0%